Loading
IARC estimates 3,326 new cancer cases and 1,460 cancer deaths in Qatar in 2024; the commonest new cancers are breast, colorectum and trachea, bronchus and lung. This page is assembled automatically from OnCo's data: 2 trials with a site there, 1 institution and 1 person, and says what OnCo does not yet hold.
| Site | New cases | Rate | OnCo page |
|---|---|---|---|
| Breast | 440 | 61.8 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Colorectum | 415 | 21.3 | Colorectal cancer |
| Trachea, bronchus and lung | 223 | 12.9 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Prostate | 204 | 25.0 | Prostate cancer |
| Non-Hodgkin lymphoma | 189 | 7.3 | Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma |
| Brain, central nervous system | 178 | 5.8 | Glioma & glioblastoma |
| Thyroid | 173 | 5.1 | Thyroid cancer |
| Hodgkin lymphoma | 167 | 4.0 | Hodgkin lymphoma |
| Leukaemia | 151 | 6.6 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia |
| Testis | 113 | 2.6 | Testicular germ cell tumours |
| Site | Deaths | Rate | OnCo page |
|---|---|---|---|
| Trachea, bronchus and lung | 201 | 11.5 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Colorectum | 180 | 10.1 | Colorectal cancer |
| Brain, central nervous system | 145 | 5.0 | Glioma & glioblastoma |
| Breast | 116 | 18.0 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Liver and intrahepatic bile ducts | 93 | 7.6 | Hepatocellular carcinoma |
| Leukaemia | 89 | 4.5 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia |
| Pancreas | 68 | 3.8 | Pancreatic ductal adenocarcinoma |
| Non-Hodgkin lymphoma | 66 | 2.6 | Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma |
| Prostate | 56 | 6.5 | Prostate cancer |
| Stomach | 54 | 3.4 | Gastric & gastro-oesophageal junction cancer |
| Trial | Lead sponsor | ||||
|---|---|---|---|---|---|
| Phase 3 | Active not recruiting | AstraZeneca | 210 | 2026-08-06 | |
| Phase 3 | Active not recruiting | Day One Biopharmaceuticals, Inc. | 138 | 2026-05-14 |
Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Qatar, captured 2026-10-07 to 2026-10-07. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Qatar is open is on the registry page, under Contacts and Locations.
People whose main affiliation in OnCo is an institution or company in Qatar.
OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Qatar is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.
Qatar is not among the 60 countries ranked in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.